How has been the historical performance of Ipca Labs?

Answer:The historical performance of Ipca Labs shows a consistent growth in net sales and profit over the years, with net sales reaching 8,939.59 Cr in March 2025, up from 7,705.04 Cr in March 2024 and 6,244.32 Cr in March 2023. The total operating income mirrored this trend, increasing to 8,939.59 Cr in March 2025. The operating profit (PBDIT) also saw a rise, reaching 1,818.94 Cr in March 2025 compared to 1,445.93 Cr in March 2024. However, profit after tax showed fluctuations, peaking at 1,148.84 Cr in March 2021 before declining to 787.53 Cr in March 2025. The earnings per share (EPS) increased to 29.08 in March 2025 from 21.57 in March 2024, indicating improved profitability per share.

Breakdown:
Ipca Labs has demonstrated a strong upward trajectory in its financial metrics over the years. From March 2019 to March 2025, net sales grew significantly from 3,773.18 Cr to 8,939.59 Cr, reflecting a robust demand for its products. The total expenditure also increased, but at a slower pace, leading to a rise in operating profit, which reached 1,818.94 Cr in March 2025. Despite some fluctuations in profit after tax, which peaked at 1,148.84 Cr in March 2021 before dropping to 787.53 Cr in March 2025, the company maintained a healthy operating profit margin of 19.31% in March 2025. The balance sheet shows a steady increase in total assets, reaching 11,743.63 Cr in March 2025, while total liabilities also rose to 11,743.63 Cr, indicating a balanced growth in the company's financial structure. The cash flow from operating activities improved to 1,321.00 Cr in March 2025, contributing to a net cash inflow of 168.00 Cr, a positive shift from the previous year. Overall, Ipca Labs has shown resilience and growth in its financial performance, positioning itself favorably in the market.